← Leaderboards
Shannon Gwin Mitchell
Friends Research Institute, Inc.
$12,341,607
Attributed
$18,197,733
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2009–22$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$18,197,733 · 6
By mechanism
UG1$9,160,462 · 1
R01$5,296,869 · 2
U01$2,551,790 · 1
RC1$990,091 · 1
R41$198,521 · 1
Top collaborators
- Michael Scott Gordon6 shared
- D. Brad Rindal4 shared
Most similar at Friends Research Institute, Inc.
Same institution · by research overlap
- Robert P Schwartz$28,126,650
Others in their field
Top investigators on “Randomized”
- James Dennis Neaton · Northwestern University$305,243,252
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$292,521,996
- Lawrence Corey · Fred Hutchinson Cancer Center$292,521,996
- Marian Ewell · The Emmes Company, Llc$278,931,253
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$199,647,509
- Beth Baseler · Leidos Biomedical Research, Inc.$194,920,310
Research focus
RandomizedOpioidInnovationEffectivenessDrug UsagePharmaceutical PreparationsOverdoseCostRisk BehaviorsCommunitiesSafetyPrescription OpioidRelapseBuprenorphinePublic HealthTreatment ProgramOpiate AddictionCrimeNaltrexoneOpioid UseRandomized TrialPharmacotherapyAlcohol ConsumptionClinical Trials
Grant awards (22)
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,169,367
UG1 · FY2022 · DA
A comparison of Sublingual and Extended-Release Buprenorphine for Individuals Leaving Jail$678,563
UG1 · FY2022 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,216,013
UG1 · FY2021 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$165,428
UG1 · FY2021 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,231,473
UG1 · FY2020 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$1,699,618
UG1 · FY2019 · DA
De-Implementing Opioid Use and Implementing Optimal Pain Management Following Dental Extractions$680,295
U01 · FY2019 · DE
De-Implementing Opioid Use and Implementing Optimal Pain Management Following Dental Extractions$731,356
U01 · FY2018 · DE
Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth$667,142
R01 · FY2018 · DA · contact PI
De-Implementing Opioid Use and Implementing Optimal Pain Management Following Dental Extractions$355,000
U01 · FY2018 · DE
De-Implementing Opioid Use and Implementing Optimal Pain Management Following Dental Extractions$785,139
U01 · FY2017 · DE
Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth$658,191
R01 · FY2016 · DA · contact PI
Computerizing NIAAA's Best Practices for Youth Screening and Brief Intervention$198,521
R41 · FY2016 · AA · contact PI
Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth$622,812
R01 · FY2015 · DA · contact PI
SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers$448,115
R01 · FY2015 · DA · contact PI
Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth$661,668
R01 · FY2014 · DA · contact PI
SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers$500,163
R01 · FY2014 · DA · contact PI
Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth$659,559
R01 · FY2013 · DA · contact PI
SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers$480,177
R01 · FY2013 · DA · contact PI
SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers$599,042
R01 · FY2012 · DA · contact PI
Intensive Outpatient v. Outpatient Treatment with Buprenorphine among African Ame$491,343
RC1 · FY2010 · DA · contact PI
Intensive Outpatient v. Outpatient Treatment with Buprenorphine among African Ame$498,748
RC1 · FY2009 · DA · contact PI